Literature DB >> 28723517

Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey.

Renée Bultijnck1, Cristian Surcel2, Guillaume Ploussard3, Alberto Briganti4, Pieter De Visschere5, Jurgen Fütterer6, Pirus Ghadjar7, Gianluca Giannarini8, Hendrik Isbarn9, Christophe Massard10, Prasanna Sooriakumaran11, Massimo Valerio12, Roderick van den Bergh13, Piet Ost14.   

Abstract

BACKGROUND: Evidence-based recommendations are available for the management of androgen deprivation therapy (ADT)-induced side effects; however, there are no data on the implementation of the recommendations into daily practice patterns.
OBJECTIVE: To compare practice patterns in the management of ADT-induced side effects with evidence-based strategies. DESIGN, SETTING, AND PARTICIPANTS: A European Web-based survey was conducted from January 16, 2015, to June 24, 2015. The 25-item questionnaire was designed with the aid of expert opinion and covered general respondent information, ADT preference per disease stage, patient communication on ADT-induced side effects, and strategies to mitigate side effects. All questions referred to patients with long-term ADT use. Reported practice patterns were compared with available evidence-based strategies. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Following data collection, descriptive statistics were used for analysis. Frequency distributions were compiled and compared using a generalised chi-square test. RESULTS AND LIMITATIONS: In total, 489 eligible respondents completed the survey. Luteinising hormone-releasing hormone-agonist with or without an antiandrogen was the preferred method of ADT in different settings. Patients were well informed about loss of libido (90%), hot flushes (85%), fatigue (67%), and osteoporosis (63%). An osteoporotic and metabolic risk assessment prior to commencing ADT was done by one-quarter of physicians. The majority (85%) took preventive measures and applied at least one evidence-based strategy. Exercise was recommended by three-quarters of physicians who advocate its positive effects; however, only 25% of physicians had access to exercise programmes. Although the minimum sample size was set at 400 participants, the current survey remains susceptible to volunteer and nonresponder bias.
CONCLUSIONS: Patients were well informed about several ADT-induced complications but uncommonly underwent an osteoporotic and metabolic risk assessment. Nevertheless, physicians partially provided evidence-based strategies for the management of the complications. Physicians often advised exercise to reduce ADT-induced side effects, but programmes were not widely available. PATIENT
SUMMARY: Implementation of evidence-based strategies for androgen deprivation therapy-induced side effects in real-life practice patterns should be improved.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adverse effects; Androgen deprivation therapy; Prostatic neoplasms; Survey

Year:  2016        PMID: 28723517     DOI: 10.1016/j.euf.2016.02.009

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


  3 in total

1.  Rehabilitation interventions to improve patient-reported outcomes and physical fitness in survivors of muscle invasive bladder cancer: a systematic review protocol.

Authors:  Elke Rammant; Renée Bultijnck; Nora Sundahl; Piet Ost; Nele S Pauwels; Benedicte Deforche; Ronny Pieters; Karel Decaestecker; Valérie Fonteyne
Journal:  BMJ Open       Date:  2017-06-06       Impact factor: 2.692

2.  Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach.

Authors:  Xavier Bonfill; Ingrid Arevalo-Rodriguez; Laura Martínez García; Maria Jesús Quintana; Diana Buitrago-Garcia; Diego Lobos Urbina; José Antonio Cordero
Journal:  Cancer Manag Res       Date:  2018-08-02       Impact factor: 3.989

3.  Androgen deprivation monotherapy usage in non-metastatic prostate cancer: results from eight European countries.

Authors:  Dionysios Mitropoulos; Piotr Chlosta; Michael Häggman; Torbjorn Ström; Vyron Markussis
Journal:  Cent European J Urol       Date:  2021-03-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.